In 2025, Castle achieved total test reports for core revenue drivers (DecisionDx-Melanoma and TissueCypher) increasing 37% over 2024, and exceeded full-year revenue guidance at $344 million. The company maintains strong analyst sentiment with an average "Strong Buy" rating and a 12-month stock price target of $47.17, representing an 84.55% upside from current levels.
Cyborg Score Rationale
Castle demonstrates strong fundamentals with 37% growth in core test volumes (2025), significant revenue expansion to $344M, and robust analyst conviction. The company operates in high-margin diagnostic testing with expanding clinical validation. Key risk factors include market adoption rates and competitive pressures in molecular diagnostics.
Top Insights
(February 2026) Publication of prospective, multicenter study validating DecisionDx-Melanoma's integrated SLNB test result, strengthening clinical evidence base
(February 2026) Exceeded 2025 full-year revenue guidance with $344M in total revenue, demonstrating operational execution and demand strength
Core revenue drivers DecisionDx-Melanoma and TissueCypher showed 37% growth in test volume in 2025, indicating strong market adoption and penetration
Diversifying test portfolio beyond skin cancer into gastroenterology (Barrett's esophagus), dermatology (atopic dermatitis), and mental health (pharmacogenomics), reducing single-indication revenue risk
Named Competitors
Guardant360 — Liquid biopsy platform for cancer detection and monitoring
MyRisk — Genetic testing and cancer risk assessment
Oncotype DX — Genomic cancer diagnostics and treatment planning
Recent Developments
(March 2026) Published prospective multicenter study results evaluating DecisionDx-Melanoma's integrated SLNB test capabilities
(February 2026) Announced 2025 full-year revenue of $344 million, exceeding guidance with 37% growth in core test volumes